AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24868098 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day)
Number of subjects: 174
Study 24868098 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based doublet chemotherapy
Number of subjects: 174
Study 22488006 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (3 mL, 10 units/mL)
Number of subjects: 341
Study 22488006 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (NaCl, 10 mL)
Number of subjects: 341
Study 22488006 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 341
Study 22488006 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride
Number of subjects: 341
Study 22488006 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure‐injectable central venous catheters
Number of subjects: 341
Study 19282274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of perindopril and indapamide
Number of subjects: 11140
Study 19282274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11140
Study 17900994 — intervention group
Group type: EXPERIMENTAL
Intervention: Asimadoline, up to 1 mg 4 times daily
Number of subjects: 100
Study 17900994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17900994 — intervention group
Group type: EXPERIMENTAL
Intervention: Asimadoline
Number of subjects: 100
Study 15287950 — intervention group
Group type: EXPERIMENTAL
Intervention: Education about warfarin
Number of subjects: 125
Study 15287950 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and self-monitoring
Number of subjects: 125
Study 15287950 — intervention group
Group type: COMPARATOR
Intervention: Usual clinic care
Number of subjects: 125
Study 15287950 — intervention group
Group type: EXPERIMENTAL
Intervention: Education alone
Number of subjects: 125
Study 15287950 — intervention group
Group type: EXPERIMENTAL
Intervention: Education or education and self-monitoring
Number of subjects: 125
Study 12373472 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (initial bolus 0.5 mg/kg followed by continuous infusion of 2.5 micro g/kg per minute until the 2nd postoperative day)
Number of subjects: 40
Study 12373472 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 40
Study 12373472 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 40
Study 9191584 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg body weight)
Number of subjects: 0
Study 9191584 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose in decaffeinated coffee)
Number of subjects: 0
Study 1539785 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% propofol
Number of subjects: 0
Study 1539785 — intervention group
Group type: COMPARATOR
Intervention: 1% propofol
Number of subjects: 0
Study 3886153 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg four times daily for 8 weeks)
Number of subjects: 33
Study 3886153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 31202902 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 28
Study 31202902 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 28
Study 29528941 — intervention group
Group type: EXPERIMENTAL
Intervention: UNITY peer support workshop
Number of subjects: 239
Study 29528941 — intervention group
Group type: COMPARATOR
Intervention: breast cancer education control group
Number of subjects: 239
Study 27216354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pack
Number of subjects: 99
Study 27216354 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 99
Study 27216354 — intervention group
Group type: COMPARATOR
Intervention: No cold pack
Number of subjects: 99
Study 25326163 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium plus usual care
Number of subjects: 56
Study 25326163 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 56
Study 22270468 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration of 160 mL of levobupivacaine with adrenaline
Number of subjects: 96
Study 22270468 — intervention group
Group type: COMPARATOR
Intervention: No local infiltration
Number of subjects: 96
Study 20545574 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative radiotherapy (RT)
Number of subjects: 0
Study 20545574 — intervention group
Group type: COMPARATOR
Intervention: No post-operative radiotherapy (Control)
Number of subjects: 0
Study 17631078 — intervention group
Group type: EXPERIMENTAL
Intervention: Left pectoral implant
Number of subjects: 627
Study 17631078 — intervention group
Group type: COMPARATOR
Intervention: Right pectoral implant
Number of subjects: 627
Study 15704481 — intervention group
Group type: EXPERIMENTAL
Intervention: Phezam treatment for 8 weeks
Number of subjects: 120
Study 15704481 — intervention group
Group type: EXPERIMENTAL
Intervention: Phezam treatment for 2 months in routine practice
Number of subjects: 120
Study 11833047 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol ester-enriched margarine (20 g/d, 1.82 g/d of phytosterols)
Number of subjects: 63
Study 10610081 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (aerobic and resistance)
Number of subjects: 0
Study 10610081 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise addiction
Number of subjects: 0
Study 7793225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 24
Study 7793225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipecuronium
Number of subjects: 24
Study 7793225 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium
Number of subjects: 24
Study 7793225 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 24
Study 1678543 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium divalproex
Number of subjects: 12
Study 1678543 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 6133412 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg midazolam
Number of subjects: 43
Study 6133412 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg flunitrazepam
Number of subjects: 43
Study 6133412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 30936001 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-step intervention (automated text messages/phone calls, manual phone calls, face-to-face interviews)
Number of subjects: 1220
Study 30936001 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation letter (control group)
Number of subjects: 1220
Study 29305254 — intervention group
Group type: EXPERIMENTAL
Intervention: Total abdominal hysterectomy
Number of subjects: 381
Study 29305254 — intervention group
Group type: COMPARATOR
Intervention: Total laparoscopic hysterectomy
Number of subjects: 381
Study 27966409 — intervention group
Group type: EXPERIMENTAL
Intervention: Men's Safer Sex website plus usual care (n=84)
Number of subjects: 159
Study 27966409 — intervention group
Group type: COMPARATOR
Intervention: Usual clinic care only (n=75)
Number of subjects: 159
Study 24503762 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline uric acid
Number of subjects: 0
Study 24503762 — intervention group
Group type: EXPERIMENTAL
Intervention: Time‐varying uric acid increase
Number of subjects: 0
Study 24503762 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcome
Number of subjects: 0
Study 22699924 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IV furosemide
Number of subjects: 0
Study 22699924 — intervention group
Group type: COMPARATOR
Intervention: Low-dose IV furosemide
Number of subjects: 0
Study 22699924 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of IV furosemide
Number of subjects: 0
Study 22699924 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus infusion of IV furosemide
Number of subjects: 0
Study 20678688 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of esomeprazole 40 mg
Number of subjects: 24
Study 20678688 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of esomeprazole 40 mg
Number of subjects: 24
Study 20678688 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of test and reference formulations
Number of subjects: 24
Study 17416124 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-C2 self-sustained natural apophyseal glide (SNAG)
Number of subjects: 32
Study 17416124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 16239128 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y gastric bypass surgery
Number of subjects: 350
Study 16239128 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary interventions of differing macronutrient composition
Number of subjects: 350
Study 16239128 — intervention group
Group type: EXPERIMENTAL
Intervention: Diverse pharmacologic interventions
Number of subjects: 350
Study 16239128 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 350
Study 12201829 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy (continuous for 9 years)
Number of subjects: 85
Study 12201829 — intervention group
Group type: COMPARATOR
Intervention: No GH replacement therapy
Number of subjects: 85
Study 9843170 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa 90 microg/kg
Number of subjects: 29
Study 9843170 — intervention group
Group type: COMPARATOR
Intervention: rFVIIa 35 microg/kg
Number of subjects: 29
Study 9843170 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa 90 microg/kg (open-label after day 5)
Number of subjects: 29
Study 7521636 — intervention group
Group type: EXPERIMENTAL
Intervention: APDT vaccines (liquid and freeze-dried)
Number of subjects: 89
Study 7521636 — intervention group
Group type: COMPARATOR
Intervention: WCPDT vaccine
Number of subjects: 89
Study 2658335 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ml NaCl with 25 ml Ginkgo‐biloba‐extract
Number of subjects: 24
Study 2658335 — intervention group
Group type: COMPARATOR
Intervention: 250 ml NaCl without Ginkgo‐biloba‐extract
Number of subjects: 24
Study 31500590 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional shared decision making (IP-SDM) training for home care teams
Number of subjects: 296
Study 31500590 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver characteristics
Number of subjects: 296
Study 31500590 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship characteristics
Number of subjects: 296
Study 31500590 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver's perception of social support resources
Number of subjects: 296
Study 27145299 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodized salt intervention
Number of subjects: 1602
Study 27145299 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-iodized salt)
Number of subjects: 1602
Study 27145299 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodized salt intervention (with mother's education as effect modifier)
Number of subjects: 1602
Study 27145299 — intervention group
Group type: COMPARATOR
Intervention: Control group (with mother's education as effect modifier)
Number of subjects: 1602
Study 25559589 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,600 nm CO2 fractional laser (energy = 10 mJ; density = 10%; spot size = 7 mm; pulse = 1)
Number of subjects: 20
Study 25559589 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated scar half)
Number of subjects: 20
Study 23264827 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical care pathway implementation
Number of subjects: 114
Study 19714349 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroid (n = 12)
Number of subjects: 24
Study 19714349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 24
Study 18474024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (CsA) and/or methotrexate (MTX) for GVHD prophylaxis
Number of subjects: 0
Study 18474024 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging strategies for GVHD prophylaxis
Number of subjects: 0
Study 15793525 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-herbal combination of Eleutherococcus, Achillea millefolium, and Lamium album
Number of subjects: 49
Study 15793525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 12483453 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (20 mg day(-1))
Number of subjects: 17
Study 12483453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 10051081 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 43
Study 10051081 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 43
Study 7564084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool dialysate (35.0 degrees C)
Number of subjects: 9
Study 7564084 — intervention group
Group type: COMPARATOR
Intervention: Warm dialysate (37.5 degrees C)
Number of subjects: 9
Study 2267679 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(9) irradiation‐killed M. vaccae
Number of subjects: 38
Study 2267679 — intervention group
Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 38
Study 2267679 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin plus murabutide plus 10(9) irradiated M. vaccae
Number of subjects: 38
Study 2267679 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoclaved preparation of 10(9) M. vaccae
Number of subjects: 38
Study 2267679 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 10(9) irradiated M. vaccae
Number of subjects: 38
Study 2267679 — intervention group
Group type: EXPERIMENTAL
Intervention: Most effective modifications
Number of subjects: 38
Study 2267679 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoclaved bacilli
Number of subjects: 38
Study 7398003 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone
Number of subjects: 154
Study 7398003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 31926496 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 72
Study 31926496 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 72
Study 29776383 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face psychoeducation
Number of subjects: 279
Study 29776383 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone assisted self-help (TASH)
Number of subjects: 279
Study 29776383 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group (3-month waiting period)
Number of subjects: 279
Study 29776383 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling (for full responders)
Number of subjects: 279
Study 29776383 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling only or Counseling and neurofeedback (for partial responders)
Number of subjects: 279
Study 29776383 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment only or Pharmacological treatment and neurofeedback (for non-responders)
Number of subjects: 279
Study 27504751 — intervention group
Group type: EXPERIMENTAL
Intervention: Common Sense Parenting (CSP)
Number of subjects: 321
Study 27504751 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP-Plus
Number of subjects: 321
Study 27504751 — intervention group
Group type: COMPARATOR
Intervention: Minimal-contact control condition
Number of subjects: 321
Study 24615831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimacy Enhancement (IE) intervention
Number of subjects: 23
Study 24615831 — intervention group
Group type: COMPARATOR
Intervention: Wait list control condition
Number of subjects: 23
Study 23220809 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrotherapy and exercise (hotpack application, ultrasound, and exercise training)
Number of subjects: 60
Study 23220809 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 60
Study 23220809 — intervention group
Group type: COMPARATOR
Intervention: Control group (two weeks rest)
Number of subjects: 60
Study 19714757 — intervention group
Group type: EXPERIMENTAL
Intervention: Visilizumab 5 microg/kg/day for 2 days
Number of subjects: 104
Study 19714757 — intervention group
Group type: EXPERIMENTAL
Intervention: Visilizumab 7.5 microg/kg/day for 2 days
Number of subjects: 104
Study 19714757 — intervention group
Group type: EXPERIMENTAL
Intervention: Visilizumab 10 microg/kg/day for 2 days
Number of subjects: 104
Study 19714757 — intervention group
Group type: EXPERIMENTAL
Intervention: Visilizumab 12.5 microg/kg/day for 2 days
Number of subjects: 104
Study 18694678 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-compound scalp formulation (calcipotriene 50 microg/g plus betamethasone 0.5 mg/g)
Number of subjects: 1505
Study 18694678 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone 0.5 mg/g (as dipropionate) in the same vehicle
Number of subjects: 1505
Study 18694678 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriene 50 microg/g in the same vehicle
Number of subjects: 1505
Study 18694678 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 1505
Study 16235126 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted peritoneal catheter placement
Number of subjects: 100
Study 16235126 — intervention group
Group type: COMPARATOR
Intervention: Standard transrectal or pararectal approach
Number of subjects: 100
Study 12180317 — intervention group
Group type: EXPERIMENTAL
Intervention: F0 (braking force)
Number of subjects: 36
Study 12180317 — intervention group
Group type: EXPERIMENTAL
Intervention: Pmax (maximal anaerobic power)
Number of subjects: 36
Study 10598609 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 274
Study 10598609 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 274
Study 10598609 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 274
Study 7489236 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 41
Study 7489236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 2037541 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (50 mg in one single daily dose)
Number of subjects: 50
Study 2037541 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B (200 mg four times daily)
Number of subjects: 50
Study 7044802 — intervention group
Group type: EXPERIMENTAL
Intervention: benoxaprofen
Number of subjects: 1403
Study 7044802 — intervention group
Group type: COMPARATOR
Intervention: comparator drugs (diclofenac, indomethacin, flurbiprofen, piroxicam)
Number of subjects: 1403
Study 30614222 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based environmental control intervention (INT)
Number of subjects: 222
Study 30614222 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 222
Study 26443484 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine oral rinse
Number of subjects: 94
Study 26443484 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 94
Study 24528246 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose metformin (50% reduction)
Number of subjects: 0
Study 24528246 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of glimepiride
Number of subjects: 0
Study 22958507 — intervention group
Group type: EXPERIMENTAL
Intervention: WATER therapy program (24 sessions, 3 times/week over 8 weeks) of low-intensity exercises in a warm pool (32°C)
Number of subjects: 66
Study 22958507 — intervention group
Group type: EXPERIMENTAL
Intervention: WATER therapy program
Number of subjects: 66
Study 22958507 — intervention group
Group type: COMPARATOR
Intervention: CONTROL group (usual care treatment for breast cancer)
Number of subjects: 66
Study 19687337 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of supervised aerobic exercise training (AET)
Number of subjects: 122
Study 17595415 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg Zn/d for 6 months
Number of subjects: 100
Study 17595415 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Zn/d for 6 months
Number of subjects: 100
Study 17595415 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Zn intake (diet plus supplementation) of up to 40 mg Zn/d
Number of subjects: 100
Study 15964291 — intervention group
Group type: EXPERIMENTAL
Intervention: Nestorone/ethinyl estradiol ring releasing 50/10 mug/day
Number of subjects: 160
Study 15964291 — intervention group
Group type: EXPERIMENTAL
Intervention: Nestorone/ethinyl estradiol ring releasing 50/20 mug/day
Number of subjects: 160
Study 15964291 — intervention group
Group type: EXPERIMENTAL
Intervention: Nestorone/ethinyl estradiol ring releasing 150/15 mug/day
Number of subjects: 160
Study 15964291 — intervention group
Group type: EXPERIMENTAL
Intervention: Nestorone/ethinyl estradiol rings (all doses)
Number of subjects: 160
Study 11929402 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (800 mg/day)
Number of subjects: 3993
Study 11929402 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (150 mg/day)
Number of subjects: 3993
Study 10064240 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole, 2.5 mg/kg every 12 hours
Number of subjects: 405
Study 10064240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 7501737 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% CO2 inhalation
Number of subjects: 99
Study 2083942 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 191
Study 2083942 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 191
Study 763004 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Patient Orientation (APO)
Number of subjects: 0
Study 763004 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental changes in systems of routine clinic care
Number of subjects: 0
Study 30834862 — intervention group
Group type: EXPERIMENTAL
Intervention: Quo-Test HbA1c POCT
Number of subjects: 266
Study 30834862 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control group)
Number of subjects: 266
Study 28715852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent drospirenone/ethinyl estradiol dosed on a 21-7 schedule (n = 17)
Number of subjects: 55
Study 28715852 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous drospirenone/estradiol (n = 16)
Number of subjects: 55
Study 28715852 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 55